Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Adocia (ADOC) EUR0.10

Sell:€7.94 Buy:€8.14 Change: €0.02 (0.25%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
Change: €0.02 (0.25%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
Change: €0.02 (0.25%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adocia SA, also known as Adocia, is a France-based company engaged in the biotechnology business sector. It specializes in the research and development of biotherapy products used in tissue regeneration and for treating chronic diseases. The Company develops a BioChaperone Platform used for therapeutic protein delivery in regenerative medicine and chronic disease areas, such as wound Healing, diabetes, ulcers and monoclonal antibody creation. The Company completed two Phases I and II studies of the formulation of human insulin, two Phases I and II studies of insulin lispro and one Phase I/II on a combination of insulin glargine, the basal insulin and insulin lispro, an insulin analog. Adocia also undertaken the activities in the field of formulation of monoclonal antibodies which are molecules for the treatment of various chronic pathologies (oncology, inflammation, etc.).

Contact details

115 avenue Lacassagne
+33 (4) 72610610

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€56.24 million
Shares in issue:
6.95 million
Euronext Paris

Key personnel

  • Gerard Soula
    Chairman of the Board, Chief Executive Officer
  • Olivier Soula
    Deputy Chief Executive Officer, Vice President - Research & Development, Director
  • Valerie Danaguezian
    Chief Financial Officer, Administrative Director
  • You-Ping Chan
    Scientific Director
  • Remi Soula
    Business Development and Intellectual Property Director
  • Geraldine Soula
    Director of Development and Human Resources
  • Bertrand Alluis
    Head of Analysis Department and Project Manager
  • Richard Charvet
    Head of Chemistry Department
  • Jose Correia
    Head of the Preclinical and Clinical Department, HSQE Manager and Project Manager
  • David Duracher
    Head of Pharmaceutical Development and Physical Chemistry Departments

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.